Reducing CI-AKI Incidence in TAVR Procedures

Reducing CI-AKI Incidence in TAVR Procedures

Prof Nikos Werner

Head of Cardiology/Head of the Trier Heart Center, Germany

Specialist in Internal Medicine/Cardiology
Additional designation: Internal Intensive Care Medicine;
Additional qualification: Interventional Cardiology (DGK), Interventional Angiology (DGK), Hypertensiology (DHL)

Nikos Werner, MD, PhD, is Professor and Director of the Heart Center Trier and the Department of Internal Medicine III – Cardiology and Intensive Care Medicine at the Hospital Barmherzige Brüder Trier, Germany. He received his medical training in Frankfurt, Louisville, and New York. His scientific and clinical career was accomplished at the University Hospitals in Homburg and Bonn. With the development of TAVR, his interest shifted towards its clinical application and scientific evaluation culminating in various publications. Until today, he has published more than 200 articles in peer-reviewed journals. He is PI in a number of interventional studies and has initiated a number of Investigator-Initiated trials. Professor Werner was awarded several clinical and translational scientific awards.

Interview with Prof Werner (Heart Center Trier, Germany)

EXPAND

Watch Full Interview

Q1: What are the biggest challenges you face in your cath lab?

Q2: How do you integrate the ACIST CVi into TAVR and cardiac procedures?

Q3: Describe your experience with TAVR procedures

Q4: How do you reduce kidney injuries in TAVR patients?

Q5: Describe a typical TAVR patient and how this may impact the procedure and outcome

Q6: How do you manage TAVR procedures in patients with renal insufficiency?

Q7: What benefits do you see in using the ACIST CVi?

Q8: How does the ACIST CVi help you focus on the patient?

Watch Full Interview

Q1: What are the biggest challenges you face in your cath lab?

Q2: How do you integrate the ACIST CVi into TAVR and cardiac procedures?

Q3: Describe your experience with TAVR procedures

Q4: How do you reduce kidney injuries in TAVR patients?

Q5: Describe a typical TAVR patient and how this may impact the procedure and outcome

Q6: How do you manage TAVR procedures in patients with renal insufficiency?

Q7: What benefits do you see in using the ACIST CVi?

Q8: How does the ACIST CVi help you focus on the patient?

  • Bracco個人情報保護プログラム

     こちらからご覧ください。

  • 個人情報保護方針

     こちらからご覧ください。

  • 利用目的

     こちらからご覧ください。

日本での個人情報保護法の取扱い

個人情報に関するお問合せは下記の窓口へご連絡ください。

個人情報担当窓口

ブラッコ · ジャパン株式会社

法務コンプライアンス部

住   所 :〒171-0022 東京都豊島区南池袋1-13-21 PMO池袋II

電話番号: 03-5319-3381

Skip to content